Interleukin-10 Staining Provides Important Prognostic Information in Nasopharyng
Interleukin-10 Staining Provides Important Prognostic Information in Nasopharyngeal Carcinoma
abstract & commentary
Synopsis: Nasopharyngeal cancer cells were shown to express IL-10 by immunohistochemistry. The results of this study imply that expression of IL-10 is a prognostic factor in patients with nasopharyngeal cancer and may prove useful in development of treatment strategies.
Source: Fujieda S, et al. Cancer 1999;85:1439-1445.
Interleukin-10 (il-10) is an important modulator of lymphocyte function with generally immunosuppressive properties.1 Its production by a variety of tumor cells including lymphoma2 and melanoma3 has been associated with more aggressive tumor characteristics, and shortened survival. The association between Epstein-Barr virus (EBV) and nasopharyngeal carcinoma (NPC) has been appreciated for two decades. Recently, EBV-encoded RNA signals were identified in nuclei of malignant cells in 96.4% of primary NPC tumors.4 It has now also been appreciated that the EBV genome produces a protein (designated viral-IL-10) with extensive homology to human IL-10, and like human IL-10, v-IL-10 inhibits cytokine production by human peripheral blood mononuclear cells.4
In this report, Fujieda and colleagues investigated the expression of IL-10 in 21 primary nasopharyngeal cancers using immunohistochemical techniques. IL-10 staining was positive in 12 of 21 (57%). There was no association between IL-10 expression and gender, tumor size, the occurrence of lymph node metastases, clinical stage, or recurrence. However, there was a significant difference in overall survival between those that stained negative and positive for IL-10. Although 87% of the IL-10 negative group survived for five years, only 15% of the IL-10 positive patients survived that long. Using multivariate analysis, IL-10 expression was significant as an independent prognostic indicator of overall survival. Fujieda et al propose that IL-10 staining of primary NPC may be useful in selecting patients at all stages for aggressive treatment.
COMMENTARY
Fujieda et al found that there was a bimodal distribution of IL-10 expression in tumors from patients with NPC. An IL-10 staining score of less than 10% was considered negative, whereas a score of more than 30% was positive. The IL-10 score in patients with Stage IV disease was higher than those with Stage II or Stage III, but this difference was not significant by one-way analysis of variance. Furthermore, there was no association between IL-10 expression and tumor size, lymph node status, clinical stage, or recurrence. Yet, the IL-10 score was significantly correlated with death from disease. Nine patients died of disease in this study, and their IL-10 staining score was 65%, compared to a score of 28% in those who survived.
Thus, IL-10 staining was a useful independent prognostic indicator in patients with NPC. Why this would be the case is a matter of conjecture. However, it might relate to the function of IL-10, which is generally immunosuppressive. Not only does IL-10 inhibit other cytokine production, it has been shown to inhibit specific T-cell functions, antigen presentation, and macrophage function in various tumor immunity models.5-7 A local production of IL-10 within the NPC microenvironment might undermine local immune or inflammatory responses that would otherwise inhibit growth.
Another proposed mechanism of tumor-enhancement by IL-10 relates to its potential as a direct growth factor. For example, melanoma cells have been shown to express both IL-10 and IL-10 receptor, and anti IL-10 antibody decreased spontaneous proliferation of cells.8 This would suggest that IL-10 might function as an autocrine growth factor for melanoma. Whether this is true for other tumor types, such as NPC, remains to be investigated.
Finally, IL-10 staining in NPC tumors may well relate to its association with EBV. The strong association with IL-10 expression and patient survival suggests that its immunosuppressive, or direct tumor- enhancing properties, may be of clinical importance. High tumor IL-10 expression was found in approximately one-half of NPC patients, and it was a strong, independent predictor of survival. Clinicians and clinical investigators might benefit from assessing this tumor characteristic when developing treatment strategies.
References
1. Malefyt RW, et al. J Exp Med 1991;174:915-924.
2. Blay JY, et al. Blood 1993;82:2169-2174.
3. Sato T, et al. Clin Cancer Res 1996;2:1383-1390.
4. Tsai ST, et al. Cancer 1996;77:231-236.
5. Kim J, et al. J Immunol 1995;155:2240-2247.
6. Qin Z, et al. J Immunol 1997;159:770-776.
7. Lacraz S, et al. J Clin Invest 1995;96:2304-2310.
8. Yue FY, et al. Int J Cancer 1997;71:630-637.
Interleukin-10 expression in primary nasopharyngeal cancers has been shown to:
a. correlate with primary tumor size.
b. correlate with lymph node status.
c. correlate with patient survival.
d. all of the above.
e. none of the above.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.